Compare NNVC & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNVC | IINN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 35.3M |
| IPO Year | N/A | 2021 |
| Metric | NNVC | IINN |
|---|---|---|
| Price | $1.25 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 359.6K | 128.4K |
| Earning Date | 11-14-2025 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $289,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,582.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.40 |
| 52 Week High | $2.23 | $1.65 |
| Indicator | NNVC | IINN |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 59.72 |
| Support Level | $1.07 | $1.03 |
| Resistance Level | $1.28 | $1.18 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.86 | 84.94 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.